Syngeneic Tumor Models | Immunocompetent Cancer Models | Ingenious Targeting Laboratory

Url: /syngeneic-tumor-models
Meta Description: Syngeneic tumor mouse models for immuno oncology research. Study tumor immune interactions in immunocompetent mouse hosts.
Primary Keyword: syngeneic mouse model
Word Count: 1500

Syngeneic Mouse Models
Since 1998, ingenious targeting laboratory has supported immuno oncology research with custom mouse models that enable syngeneic tumor studies, providing immunocompetent platforms for evaluating cancer immunotherapies, checkpoint inhibitors, and combination treatment strategies.
Syngeneic tumor models involve implanting tumor cell lines into genetically compatible mouse hosts, enabling study of tumor immunity and immunotherapy in the context of a fully functional immune system essential for translational cancer research.
Understanding Syngeneic Models
Syngeneic tumor models use tumor cell lines derived from the same inbred strain as the recipient mouse, enabling tumor growth without immune rejection.
Key Advantages
Intact Immune System
Unlike immunodeficient xenograft models, syngeneic models have functional T cells, B cells, NK cells, and myeloid populations.
Tumor Microenvironment
Immune infiltration and tumor immune interactions can be studied.
Immunotherapy Testing
Essential for checkpoint inhibitors and other immunotherapies.
Rapid Tumor Growth
Established cell lines produce consistent, reproducible tumors.
Limitations
Mouse Tumor Biology
Tumors derived from mouse cancers may differ from human cancers.
Limited Diversity
Relatively few well characterized syngeneic lines available.
Background Restrictions
Each line is specific to one inbred background.
Common Syngeneic Tumor Lines
C57BL/6 Compatible Lines
MC38 Colon Carcinoma
Widely used for checkpoint inhibitor studies. Moderate immunogenicity. Good response to anti PD1/PDL1.
B16 F10 Melanoma
Poorly immunogenic. Used for aggressive tumor studies and melanoma immunotherapy.
LLC (Lewis Lung Carcinoma)
Lung adenocarcinoma model. Moderate immunogenicity.
EL4 Lymphoma
T cell lymphoma. Rapid growth.
E0771 Breast Cancer
Mammary carcinoma model for breast cancer studies.
Panc02 Pancreatic Cancer
Pancreatic adenocarcinoma model.
BALB/c Compatible Lines
CT26 Colon Carcinoma
Highly used for immunotherapy studies. Good response to checkpoint blockade.
4T1 Breast Cancer
Aggressive mammary carcinoma. Spontaneous metastasis to lung.
EMT6 Breast Cancer
Alternative breast cancer model.
Renca Renal Carcinoma
Kidney cancer model.
A20 Lymphoma
B cell lymphoma.
Humanized Checkpoint Models
For testing human specific checkpoint antibodies:
Single Checkpoint Humanization
PD1 Humanized Mice
Mouse with human PD1 enables testing of anti human PD1 antibodies in syngeneic tumors.
PDL1 Humanized Mice
Human PDL1 expression for anti PDL1 antibody evaluation.
CTLA4 Humanized Mice
Human CTLA4 for ipilimumab class testing.
(/pd1-humanized-mice)
(/pdl1-humanized-mice)
Multi Checkpoint Humanization
Dual Humanized (PD1/CTLA4)
Both checkpoints humanized for combination studies.
Triple and Higher
PD1, PDL1, CTLA4, LAG3, TIM3 combinations.
Syngeneic Compatibility
Humanized checkpoint mice must be crossed onto appropriate backgrounds:
C57BL/6 Humanized
Compatible with MC38, B16, LLC.
BALB/c Humanized
Compatible with CT26, 4T1.
Tumor Implantation Methods
Subcutaneous
Most Common Approach
Easy tumor measurement by caliper. Simple injection technique.
Advantages
Accessible, measurable, reproducible.
Limitations
Does not replicate orthotopic tumor microenvironment.
Orthotopic
Organ Specific Implantation
Tumor implanted in organ of origin (mammary fat pad for breast, cecum for colon, etc.).
Advantages
More physiological tumor microenvironment. May affect metastasis patterns.
Limitations
More technically demanding. Some tumors difficult to measure.
Intravenous
Metastasis Models
Tail vein injection seeds tumors in lung.
Applications
Metastasis studies. Lung colonization assays.
Model Design Considerations
Background Matching
Critical Requirement
Tumor cells must match recipient mouse background exactly.
Crossing Considerations
When combining syngeneic tumors with genetically modified mice, ensure both are on the same inbred background.
Congenic Status
Ensure sufficient backcrossing (N10+) for transgenic mice used as tumor hosts.
Tumor Cell Preparation
Cell Culture
Maintain lines in appropriate conditions. Avoid excessive passage.
Cell Number
Typically 0.1 to 1 million cells per injection depending on line and application.
Injection Volume
Usually 50 to 100 μL subcutaneously.
Timing Considerations
Treatment Start
Begin therapy when tumors reach defined size (often 50 to 100 mm³).
Growth Kinetics
Different lines grow at different rates. Plan accordingly.
Phenotyping Syngeneic Studies
Tumor Measurements
Caliper Measurement
Length x width x width / 2 for volume estimation.
Frequency
Typically 2 to 3 times per week.
Endpoints
Usually 1500 to 2000 mm³ for ethical endpoints.
Survival Studies
Kaplan Meier Analysis
Survival curves for long term efficacy assessment.
Complete Response
Monitor for tumor free survival.
Immune Analysis
Tumor Infiltrating Lymphocytes
Flow cytometry for T cells, NK cells, myeloid populations.
Tumor Microenvironment
Immunohistochemistry for immune cell infiltration.
Peripheral Immune Status
Blood and spleen immune cell analysis.
Pharmacodynamics
Target Engagement
Receptor occupancy by therapeutic antibodies.
Cytokine Profiles
Serum or tumor cytokine levels.
Gene Expression
Tumor transcriptional changes.
Combination Strategies
Checkpoint Combinations
PD1 + CTLA4
Well established combination. Dual humanized mice required for human antibodies.
PD1 + LAG3
Emerging combination.
Triple Combinations
Multiple checkpoint targeting.
Other Combinations
Checkpoint + Chemotherapy
Immunotherapy combined with cytotoxic agents.
Checkpoint + Radiation
Abscopal effect studies.
Checkpoint + Targeted Therapy
BRAF, MEK, and other pathway inhibitors.
ITL's Approach to Syngeneic Models
Humanized Checkpoint Mice
ITL generates humanized checkpoint mice compatible with syngeneic tumor studies:
Background Optimization
Humanized alleles on pure C57BL/6 or BALB/c backgrounds.
Expression Validation
Confirm human checkpoint expression and function.
Tumor Compatibility
Verify syngeneic tumor growth in humanized hosts.
Additional Genetic Modifications
Combine syngeneic tumor hosts with other genetic modifications:
Knockout Hosts
Delete specific immune genes in tumor hosts.
Reporter Mice
Track specific immune populations during tumor response.
Cre Driver Lines
Cell type specific genetic manipulation in tumor microenvironment.
What Researchers Say
"The quality of service was exceptional. Your team went above and beyond to ensure that all aspects of the project were completed to the highest possible standards."

— **Albert Basson, PhD**, King's College London
(/testimonials)
Related Disease Models
	•	(/oncology-mouse-models)
	•	(/immuno-oncology-mouse-models)
	•	(/tumor-suppressor-knockout-mice)
Related Humanized Models
	•	(/pd1-humanized-mice)
	•	(/pdl1-humanized-mice)
	•	(/ctla4-humanized-mice)
	•	(/lag3-humanized-mice)
	•	(/tim3-humanized-mice)
Related Technologies
	•	(/c57bl6-mouse-background)
	•	(/humanized-mouse-models)
Frequently Asked Questions
What are the advantages of syngeneic tumor models over xenograft models?
Syngeneic models have intact immune systems (functional T cells, B cells, NK cells, myeloid populations), enabling study of tumor-immune interactions and immunotherapy testing. Xenograft models use immunodeficient hosts, preventing evaluation of immune-mediated therapeutic responses. Syngeneic models are essential for checkpoint inhibitors and other immunotherapies.
What syngeneic tumor lines are available for C57BL/6 background?
Common C57BL/6-compatible syngeneic lines include MC38 (colon carcinoma, responsive to checkpoint blockade), B16 (melanoma, poorly immunogenic), LLC (lung carcinoma), EL4 (T-cell lymphoma), E0771 (breast cancer), and Panc02 (pancreatic cancer). Selection depends on tumor type, immunogenicity, and response to immunotherapy.
Can humanized checkpoint models be combined with syngeneic tumors?
Yes. Humanized checkpoint models (PD1, PDL1, CTLA4, LAG3, TIM3) can be combined with syngeneic tumor cell lines to create systems where both tumor and immune compartments express human targets. This enables evaluation of checkpoint blockade in immunocompetent animals with intact tumor immunity, providing more physiologically relevant testing.
How do you validate syngeneic tumor model responses?
Syngeneic tumor responses are validated through tumor growth measurement (caliper measurements, bioluminescence imaging), survival analysis, immune cell infiltration (flow cytometry, immunohistochemistry), cytokine profiling, and functional assessment of immune cell activation. Models are validated before experimental use to ensure appropriate tumor growth and immune responses.
(/request-quote)
